Recall that in December 2024, Metropolis had acquired the Delhi-NCR-based Core Diagnostics, a genomics and advanced oncology testing specialist, for ₹247 crore. “Unlike SN Genelab, however, Core Diagnostics was operating only at Ebitda break-even levels at the time of the acquisition,” added Nomura. SN Genelab’s FY26 Ebitda margin stands at 26%. Dr Lal paid about 16 times SN Genelab’s FY26 Ebitda, which seems fair for a fast-growing, high-margin company.
